Lantheus Holdings, Inc. (NASDAQ:LNTH) announced its intent to acquire Life Molecular Imaging Ltd. (LMI) for $350 million in cash and an additional $400 million in potential earn out and milestone ...

BOSTON, Aug. 20, 2025 /PRNewswire/ -- Life Molecular Imaging (LMI), a Lantheus company, dedicated to developing and offering novel PET radiopharmaceuticals, has expanded its manufacturing and ...

Neuraceq® is used in clinical routine and is also a powerful diagnostic tool for the appropriate characterization of patients assessed for treatment eligibility with newly approved anti-amyloid drugs, ...

New indication added for selection of patients for amyloid-directed therapiesQuantitative image analysis addedPrevious limitations of use removed Amyloid, a naturally occurring protein, can accumulate ...

The U.S. Food and Drug Administration has approved Piramal Imaging’s Neuraceq, a positron emission tomography imaging agent to aid in diagnosing dementia, according to a company news release. Neuraceq ...

BERLIN, GERMANY and BOSTON, MA and MUMBAI, INDIA--(Marketwired - Apr 30, 2014) - Piramal Imaging today announced that data from its beta-amyloid PET tracer Neuraceq™ clinical trial will be featured as ...

BOSTON, March 14, 2025 /PRNewswire/ -- Life Molecular Imaging (LMI) and St. Teresa's Hospital are pleased to announce that Florbetaben (18F) Injection (brand name: Neuraceq ®) will be available in ...

BERLIN and BOSTON, March 20, 2014 /PRNewswire/ -- Piramal Imaging today announced that the U.S. Food and Drug Administration (FDA) has approved Neuraceq'. This approval comes only four weeks after ...

Expanded clinical indication to include use in both diagnostic assessment and identification of appropriate candidates for FDA-approved amyloid-targeting therapies. Utilization of quantitative amyloid ...

BOSTON, Oct. 7, 2025 /PRNewswire/ -- Life Molecular Imaging (LMI), a Lantheus company, and SOFIE Biosciences (SOFIE), a national US manufacturer and developer of PET radiopharmaceuticals, announce ...

Enhanced the supply capabilities of Neuraceq(R) to increase patient access to beta-amyloid PET imaging BOSTON, April 24, 2025 /PRNewswire/ -- Life Molecular Imaging (LMI) and PharmaLogic Holdings Corp ...